In a new blog post, Cato Institute Senior Health Policy Fellow, Dr. Jeffrey A. Singer critiques the FDA’s plan to pull fluoride tablets and drops from the market.
Responding to the FDA’s May 13 announcement, Singer warns that “the FDA’s proposal to remove drops and tablets from the market undermines patients’ autonomy by denying them the right to consume a product with benefits that, for them, outweigh its risks.” While he supports removing fluoride from public water systems to honor individual preferences, Singer argues it’s “an entirely different matter to deny access to fluoride for those who wish to consume it.”
If you would like to speak to Dr. Singer about this topic, please don’t hesitate to reach out to esalamon@cato.org.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.